Clinical efficacy and prognosis of sacubatrovalsartan combined with dapagliflozin in patients with heart failure with reduced ejection fraction
10.3760/cma.j.issn.1671-0282.2022.10.017
- VernacularTitle:沙库巴曲缬沙坦联合达格列净与射血分数减低的心力衰竭临床疗效及预后的相关性
- Author:
Xianlin ZHANG
1
;
Qiao LU
;
Jinlong LI
;
Yuli HUANG
;
Huiqiang YAO
;
Bi TANG
;
Heng ZHANG
Author Information
1. 蚌埠医学院第一附属医院心血管内科，蚌埠 233000
- Keywords:
Sacubatrovalsartan;
Dapagliflozin;
Heart failure;
Clinical efficacy;
Clinical prognosis
- From:
Chinese Journal of Emergency Medicine
2022;31(10):1396-1401
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and prognosis of sacubatrovalsartan combined with dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF).Methods:Totally 206 consecutive patients with HFrEF in our hospital from March 2021 to September 2021 were enrolled and randomly(random number) divided into the control group ( n = 51), the sacubatrovalsartan group ( n = 52), the dapagliflozin group ( n=51) and the combined treatment group ( n= 52). The baseline clinical data of patients and laboratory examination results were collected. The changes of related results before and after treatment in each group were analyzed and compared. After discharge, the enrolled patients were followed up by outpatient or telephone for an average of 6 months to determine whether the patients had heart failure rehospitalization, ventricular arrhythmia, major adverse cardiovascular events (MACE), etc. Results:After anti-heart failure treatment, there were significant differences in NT-proBNP, left ventricular ejection fraction (LVEF) and soluble growth stimulating gene 2 protein (ST2) among the four groups. NT-proBNP and ST2 in the combined treatment group were significantly lower than those in the other groups, and LVEF was significantly higher. Compared with the control group, the rehospitalization due to heart failure and MACE events in the other three groups were significantly lower ( P < 0.05), and the combined treatment group had the lowest ( P < 0.05). The Kaplan-Meier survival curve showed that the survival probability of the other groups was significantly higher than that of the control group, and was the highest in the combined treatment group. Conclusions:The clinical efficacy and prognosis of HFrEF patients could be significantly improved after the treatment of sacubatrovalsartan combined with dapagliflozin.
